The thesis

Replimune Group is a biotechnology company developing oncolytic immuno-gene therapies. The company has a conviction tier of 37/100, indicating a relatively low level of confidence. With a P/E ratio of -3.5x, the company's valuation is a concern. The analyst consensus rating of BUY contrasts with the low conviction score, making the setup interesting.

Why now

The current macro context, including China's chip tool push and the US-China squeeze, may impact Replimune's ability to secure funding or partnerships. The company's low conviction score and negative P/E ratio make it a compelling watchlist candidate, particularly given the analyst consensus rating of BUY.

What to watch

The company's future financial reports, particularly its revenue growth and margins, will be key indicators of its success. The outcome of upcoming clinical trials and the company's ability to secure partnerships or funding will also be important events to watch over the next 1-3 quarters.

Key risks

Valuation risk is a significant concern, given the company's negative P/E ratio. Execution risk is also a factor, as Replimune must successfully develop and commercialize its therapeutic candidates. Macro risk, including geopolitical tensions and changes in healthcare policy, could also impact the company's prospects.